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Histidine-rich glycoprotein (HRG) was purified from bovine plasma and the disulphide bridge arrangement established. Disulphide-bridged 
peptides were obtained from pepttc and tryptic degradation of native bovine HRG Twelve half-cystine residues were found in bovine HRG 
(compared to sixteen cysteines in human HRG), all involved in the formation of stx dtsulphide bridges connecting Cys-1 to Cys-12, Cys-2 to Cys-3, 
Cys-4 to Cys-5, Cys-6 to Cys-11, Cys-7 to Cys-8, and Cys-9 to Cys-10. Addittonal sequence analysis of “C-carboxymethylated chymotryptic and 
Stuphylococcus aureus V8 protease generated peptides and CNBr-fragments of bovine HRG yrelded a partial amino acid sequence of bovine HRG 
constituting 78% of the sequence when compared to the human cDNA sequence. 
Histidine-rich glycoprotein; Disulphide bond; Cystatin domain; Homology 
1. INTRODUCTION as inhibiting in vitro contact activation in human 
plasma [14]. 
Histidine-rich glycoprotein (HRG) is a single-chain 
glycoprotein of M, 75,000-8 1,000 as estimated by SDS- 
PAGE [1.2]. The protein is synthesized in the liver and 
is a negative acute-phase protein [3.4]. HRG was first 
isolated by Haupt and Heimburger in 1972 as a human 
serum protein with high affinity for CM-cellulose [5]. 
Since then, human HRG has been characterized from 
plasma [6], serum [7,8], platelets [9] and milk [lo]. In 
addition, HRG has been isolated from other species 
such as mouse [ll], rabbit [12], hog [13], and cow [14]. 
Although the exact function of HRG has not been de- 
fined, a number of biological properties of HRG have 
been revealed, establishing the concept of HRG as a 
multifunctional protein. Many of these properties imply 
that HRG physiologically may be a modulator of sev- 
eral plasma proteins involved in the blood coagulation 
and fibrinolysis. HRG has been shown to interact with 
heparin [15-l 81, plasminogen [6], thrombospondin [ 191, 
and fibrinogen [20]. HRG is capable of binding heme, 
dyes, and many divalent metal ions [7] and the protein 
is reported to inhibit autorosette formation [2] as well 
At present, the amino acid sequence of HRG from 
only one species has been determined, which is the se- 
quence of human HRG derived from the cDNA se- 
quence [21]. The mature human protein contains 507 
amino acids, including sixteen cysteine residues. N-ter- 
minally, human HRG contains two cystatin-like do- 
mains, based upon which HRG has been proposed to 
belong to the cystatin superfamily [22]. 
To gain information about conserved functional do- 
mains of HRG, comparison of the protein sequence and 
the organization of disulphide bonds between different 
species is useful. We have determined the disulphide 
bridge arrangement of bovine HRG in order to eluci- 
date the conservation of the conformation and tertiary 
structure of this multifunctional protein. 
2. MATERIALS AND METHODS 
2.1. Malerials 
Correspondence address: T.E. Petersen, Protein Chemistry Labora- 
tory, Department of Molecular Biology, The Science Park, Gustav 
Wieds Vej 10, DK-8000 Aarhus C, Denmark. Fax: (45) 86 136 597. 
Abbreviations; HRG. histidine-rich glycoprotein; DTE, dithioerythri- 
tol; Cya. cysteic acid; PTH, phenylthiohydantoin; TFA, trifluoroace- 
tic acid. 
Staphylococcus aureus V8 protease, porcine pepsin, and bovine 
TPCK-treated trypsin were supplied by Worthington (N.J.). Bovine 
TLCK-treated chymotrypsin was from Sigma (MO). Bovine pancre- 
atic trypsin inhibitor was a kind gift from L. Thim (Novo-Nordrsk, 
DK). Iodo-[2-‘4C]acetic acid (52 mCt/mmol) was supplied by Amer- 
sham International (UK). Sepharose CL-6B. Sephadex G-50 (super- 
fine), and S Sepharose fast flow were all from Pharmacia (Sweden). 
Vydac C8 resin was from The Separations Group (CA) and Nucleostl 
C,, resin was from Macherey-Nagel (FRG). ProBlott PVDF mem- 
branes and reagents for sequence analysis were from Applied Biosys- 
terns (CA). 
*This work has been presented in an abstract form (Fibrinolysis vol. 
6, suppl. 2, 1992; p. 73). 
2.2. Purification of bovme HRG 
Bovine HRG was purified from plasma by the method described 
[14], except that benzamidine. phenylmethanesulphonyl fluoride, and 
Published by Elsewer Science Publishers B. l! 285 
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bovine pancreatic trypsin Inhibitor were added to all buffers to a final 
concentration of 1 mM. 1 mM and 10 mg/l, respectively. Purified 
HRG was concentrated in an Amicon cell using a PM10 filter and 
quantified by measurmg AZkcl using the specific extinction coefficient 
/?“l:;m = 2.6 for bovine HRG determined by amino acid analysis. The 
average yield was 36-90 mg HRG/liter plasma. The isolated HRG was 
found to be pure by N-terminal sequence analysis. The purified pro- 
tem was stored at -20°C. 
2.3. S-curbo.~~i?.meth~lutlon andfkqqnentatron qf HRG 
Purified bovme HRG dissolved in 0.02 M NaH2P0,, 1 M NaCl pH 
6.3 was made 8 M m urea, 0.3 M m Tris-HCl and pH was adjusted 
to 8 3 Following denaturation, the sample was reduced with DTE. 
Y-carboxymethylated with iodo-[2-‘JC]acetic acid corresponding to 
SO-100 PCi and finally alkylated with non-labelled ICH#ZOOH. ‘“C- 
carboxymethylated HRG was dialyzed extensively against 0.1 M 
NH,HCO, before being stored at -20°C. 
Cleavage of bovine HRG was carried out m 70% formic acid with 
CNBr (l/l w/w). Degradation was allowed to occur in the dark at 
20°C for 20 h. The CNBr-degraded sample was diluted with 14 vol- 
umes of water and freeze-dried. Enzymatic fragmentation of reduced 
and “Ccarboxymethylated bovine HRG was performed in 0.1 M 
NH,HCO,. Digestion was carried out either with Staphylococcus (IU- 
yeus V8 protease (l/20 w/w, 18 h, 37°C) or with chymotrypsin (l/l00 
w/w, 19 h, 37°C.). 
Dtsulphide-bridged peptides of HRG were obtamed by degradation 
of native HRG with porcine pepsin (l/200 w/w, 4 h, 37°C) m 1% 
formic acid followed by digestion with trypsin (l/200 w/w, 2 h. 37°C) 
m 50 mM NaH,PO,. pH 6.5. All degradations were stopped by freeze- 
drying. 
2.4. Peptide imlution 
Peptide mixtures were initially fractionated by gel filtration, and 
further purification was carried out by reverse-phase HPLC using a 
Hewlett-Packard 1084B liquid chromatograph connected to a HP 
79850A LC terminal or a Pharmacia LKB 2249 HPLC. 
Peptides of ‘JC-carboxymethylated bovine HRG were separated on 
a Sephadex G-50 column in 0 1 M NH,HCO,. Absorbance was meas- 
ured at 330 nm, and aliquots of each fraction were analyzed in a liquid 
scmtillation counter. The resulting radioactive pools were further frac- 
tionated by reverse-phase HPLC with a lmear gradient of O&96% 
ethanol in 0.1% TFA at 60°C using a Vydac C,, column (300 A. 10 
pm). Absorbance was measured at 220 nm. During repurifications, a 
Nucleostl C,, column (300 A. 7 pm) and different solvents (80% ace- 
tonitrile. 70% methanol, 75% 2-propanol m 0.1% TFA) were used. 
Aliquots from each fraction were analyzed by hquid scintillation 
counting and radioactive peptides were sequenced. 
Disulphide-bridged peptides of bovme HRG were separated on a 
Sephadex G-50 column in 1% formic acid. Aliquots of every second 
fraction were subjected to performic acid oxidation and ammo acid 
analysis to determine the amount of Cya m the fractions. The obtained 
cystme-containing pools were further separated on an S Sepharose fast 
flow column with a linear gradient from 10 mM to 1 M of 
CH,COONH4 pH 5.0. Absorbance was measured at 229 nm. Aliquots 
of each of the resulting pools were measured for Cya-content and 
cystme-containing pools were subjected to reverse phase HPLC. Ini- 
tially, a Nucleosil C,, column (300 A, 7 pm) was used and peptides 
were eluted with a linear gradient of O-95% acetomtrile m 0.1% TFA 
at 20°C and monitored at 229 nm. Peptides were repurified on a Vydac 
C,, column (300 A, 10 pm) with a linear gradient of O-96% ethanol 
in 0.1% TFA at 60°C. Aliquots of all obtained fractions were analyzed 
for Cya content and cystine-containing peptides were sequenced. 
CNBr-fragments of HRG were separated on a Sepharose CL-6B col- 
umn in 8 M urea, 0.1 M CH,COONH, pH 5.0. 
2.3. Electroblottmg, unto acrd and sequence unol~sis 
Discontinuous SDS-PAGE was performed in l&20% gradient gels 
with a 4% stacking gel [23]. Gels were stained with Coomassie brilliant 
blue R. For electroblotting, proteins were transferred from an un- 
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stained SDS-PAGE gel to a ProBlott PVDF membrane [24]. The 
membrane was stained with Coomassie brilliant blue R, destamed in 
50% methanol. and washed in distilled water, 
The amino acid composition of peptides. or intact protein. was 
determined by amino acid analysis [25] after hydrolysis at 110°C for 
16 h m evacuated, sealed tubes containmg 50 ~1 6 M HCl, 0.05% 
phenol and 5 ~1 thioglycollic acid. Cystine was determined as Cya, 
generated by performic acid oxidation prior to hydrolysis. 
Automated Edman degradation was performed using an Applied 
Biosystems model 477A pulsed liquid sequencer connected on-line to 
a model 120A PTH-derivative analyzer HPLC. Typically. 100@500 
pmol of the peptide was applied per run. The amino acid sequence of 
a disulphide-bridged peptide was determined by simultaneous Edman 
degradation of the two linked peptide chains The position of the first 
half-cystine in a disulphide bridge was observed as a missing PTH- 
derivative m the actual step, whereas the second half-cystine was 
released as PTH-cystine. This derivative was observed as a peak 
eluting just in front of PTH-Tyr in the HPLC separation of PTH- 
amino acids 
2.6. Alrgnment oj protein sequences 
Protein sequences were aligned using a progressive, pairwise align- 
ment method from the program Pileup and displayed by the program 
PrettyPlot m the Genetics Computer Group Sequence Analysis Soft- 
ware Package, Version 7.1 [26]. All numbered residues in bovine HRG 
refer to the corresponding position in human HRG. 
3. RESULTS 
3.1. Isolation of “C-carbo.xyrnethylated cysteine-con- 
taining peptides 
The amount of cysteines in bovine HRG was deter- 
mined by amino acid analysis after performic acid oxi- 
dation with porcine insulin as a parallel standard. Un- 
expectedly, bovine HRG yielded only twelve cysteine 
residues compared to the sixteen cysteines predicted 
from the human cDNA sequence. Therefore, Staphylo- 
coccus aureus V8 protease and chymotrypsin digests of 
reduced and “C-carboxymethylated bovine HRG were 
performed in order to determine the positions of the 
cysteine residues. The peptide mixtures were separated 
by gel filtration and the fractions obtained were 
screened for radioactivity. Radioactive pools were fur- 
ther separated by reverse-phase HPLC. Sequencing of 
the purified peptides yielded all the twelve carbox- 
ymethylcysteines. To establish more of the amino acid 
sequence of bovine HRG some non-radioactive pep- 
tides were also isolated and their sequence determined. 
The resulting partial amino acid sequence of bovine 
HRG is shown in Fig. 1. 
3.2. Isolation of disulphide-bridged peptides 
After the positions of the twelve half-cystines had 
been established, disulphide-bridged peptides of native 
bovine HRG were isolated in order to determine the 
disulphide bridge arrangement of the protein. To gener- 
ate relatively small peptides for disulphide bridge as- 
signment, HRG was degraded successively with pepsin 
and trypsin. The risk of disulphide bridge rearrange- 
ment was minimized by the relatively low pH at which 
pepsin and trypsin treatment of HRG was carried out. 
PPPHR 
ill t iillilllllll411 II 4 
PgPffEI~KERGPGKGHFRF~~RFTGY~~~~$LKKGE 
- 
The pepticltryptic peptide mixture was fractionated on 
a Sephadex G-50 column and three cystine-comaining 
pools were subjected to further separation by cation- 
ex@hWge o.n an S Sepbarose fast Itow eobzmn. A. tata1 
of 22 ~~~~e-r~~h p&s were obtained, eaeb of WI-&& 
underwent ~~~~~a~o~ by re~erse-~~~se HPLC The 
~~r~~~ djs~~~~h~de-br~d~~~ ~t~~es were subyieeted to
~~~~o acid analysis prior to nmino aid sequencing. Six 
~~~~~~h~de-bridges ~n~bere~ LW) were assigned in 
this way. To confirm that the two peptide-strands of a 
disulphide-bridged peptide were &ctualiy linked to one 
another, performic acid oxidation of the disulphide- 
bridged peptide was carried out. The oxidized peptides 
were separated by rea7erse phase WPLG and sequenced. 
A rtumber of the peptides co~~~~.i~~~g identicd dis- 
~~~~~de bridges were foxed to ekte ia &fFerent pook 
during ca~~~-e~~~a~g~ and re9iepse pha IY3B.x dkze to 
va.riation caused by lack of pepsin qxxificity and carbo- 
hydrate heterogeneity. The resulting disulphide bridge 
a,rra~gemen~ of bovine HRG is shown in Fig. 1, wirh the 
tonge:est obtained d~s~~~~de-b~~dg~~ peptides under- 
fined* 
The ~s~~~men~ ~fd~s~~~~~de bri ge 1 in bovine ERG 
W8.s ~~~~t~ona~~y veriiied by ~so~~t~o~ mind sequencing of 
~~re~~~~d fragments obtained by ~~~r-de~adat~o~ f 
int~t bovjne HRG. The fraffn@nts were fractionated by 
~~~~~ltr~tion on a Sepharose CL-GB coiumn resulting in 
two pools {pool 1 and pool 2). SIX-PAGE of pool 1 
revealed a double band of 75 kDa similar to intact 
HRG, which also appeared as two bands of 75 kDa on 
SDS-PAGE. Whereas dectroblottirrg and sequencing of 
each of the two 75 kDa bands of iatact ZiRG revealed 
a &I& seq~ezxce o~s~~d~~g go the N-terminus of 
bovine HRG, ea& oft&e ~-SO bands from pool 1 skx~ed 
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Fig 2. A schematlc comparison of the dlsulphide loop patterns m members of the cystatin superfamdy. The disulphlde bridge arrangements of 
human cystatin C [32]. human a--glycoprotein [30]. and bovme HMM-kminogen [31] are shown. The various types of loops are denoted A, B. C, 
and D. respectively. Arrowheadsindicate the cleavage sites for kalhkrein in kminogen. and the cleavage sites in alHS-glycoprotein and bovme HRG. 
two sequences in equal amounts. The two sequences 
found in each band of pool 1 corresponded to the N- 
terminus of HRG and a fragment beginning at Arg-167. 
Thus, due to disulphide bridge I, CNBr-treated HRG 
appeared on SDS-PAGE to be identical to intact HRG. 
Reduction of the 75 kDa CNBr-fragment with DTE 
resulted in two bands of 25 kDa and 45 kDa. Sequence 
analysis demonstrated the 25 kDa-fragment to be the 
N-terminus of HRG and the 45 kDa-fragment to start 
at position Arg-167. These results are in agreement with 
the finding of only one methionine in bovine HRG by 
amino acid analysis. 
SDS-PAGE of pool 2 showed two closely spaced 
bands of about 40 kDa. Electroblotting and sequence 
analysis of the lower band revealed two sequences in 
equal amounts. corresponding to the N-terminal of 
HRG and a fragment starting at Pro-41 5. Probably, the 
peptide bond Xaa-414Pro-415 had been cleaved by 
formic acid during CNBr-treatment of HRG. Due to 
disulphide bridge I, the N-terminal-Met- 166 fragment 
and the Pro-145-Lys-507 fragment appeared as one 
band of 40 kDa. Reduction of this disulphide bridge by 
DTE produced a 10 kDa-band corresponding to the 
Pro-415-Lys-507 fragment and a 25 kDa band corre- 
sponding to the N-terminal-Met-166 fragment. The 
other half of the protein is contained in the central 
Arg-167-Xaa-414 fragment of HRG cut out by CNBr 
and formic acid cleavage. This fragment was found as 
the upper band of the 40 kDa double band. 
Despite the addition of inhibitors during purification 
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of the protein, bovine HRG was occasionally purified 
in a partly degraded form, as judged by SDS-PAGE in 
the presence of DTE. Upon reduction of the disulphide 
bridges in partly degraded bovine HRG, three bands 
appeared with an apparent molecular weight of 80 kDa. 
50 kDa, and 30 kDa, respectively. Electroblotting and 
sequencing of each band established that both the 80 
kDa and the 50 kDa bands yielded the N-terminal se- 
quence of HRG while the 30 kDa band revealed the 
sequence APLPFPPP.. ., corresponding to Ala-298 and 
forward. Consequently, the peptide-bond between Arg- 
297 and Ala-298 is sensitive to proteolysis. The degra- 
dation of bovine HRG may result from residual plasmin 
activity although a proline residue (Pro-299) is situated 
at position P2’, thereby making the site unfavourable for 
plasmin degradation. The proteolytic cleavage-site is 
indicated by an arrow in Fig. 1. 
3.3. Am-linked carbohydrate attachments and polymor- 
phism 
Peptides containing Asn-linked oligosaccharides 
were identified by observing N-acetylglucosamine in 
peptide hydrolysates. The position of Asn-linked carbo- 
hydrate was identified during sequence analysis as a 
missing PTH-derivative in the actual step. Asn-linked 
oligosaccharides were found to be attached to four Asn- 
residues in positions 74, 107, 184, and 287. All sites of 
attachment were in the carbohydrate acceptor consen- 
sus sequence Asn-Xaa-SerlThr. One site, Asn-74. was 
found to be heterogeneous with respect to carbohydrate 
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attachment and it seems most likely that this heteroge- caused by formic acid during CNBr degradation 
neity is at least partly responsible for the double band [21.28]. However, it is possible that hydrolysis at Asp- 
appearance of unreduced HRG in SDS-PAGE. 400-Pro-401 also occurs in bovine HRG. 
Three sites were found to be heterogeneous with re- 
spect to amino acid residues. Position 102 was either a 
serine or an arginine. position 420 was either a serine 
or a glutamine, whereas either a tyrosine or a histidine 
was situated at position 433. 
4. DISCUSSION 
We have identified the six disulphide bridges in bo- 
vine HRG, connecting Cys-1 and Cys-12, Cys-2 and 
Cys-3, Cys-4 and Cys-5, Cys-6 and Cys-11, Cys-7 and 
Cys-8, and Cys-9 and Cys-10. Also, a partial amino acid 
sequence of bovine HRG has been obtained, constitut- 
ing 78% of the sequence if compared to the human 
counterpart. The identity between human HRG and the 
sequenced part of bovine HRG is relatively low (65%), 
and a striking deviation exists in the number of half- 
cystines in the two proteins. Three half-cystines have 
mutated in bovine HRG, corresponding to Cys-306, 
Cys-390, and Cys-434 in human HRG. Furthermore, 
we suggest that Cys-409 and Cys-410 also have mutated 
in the bovine protein based upon the amino acid analy- 
sis of bovine HRG and the lack of finding peptide 
containing these cysteine residues. On the other hand, 
bovine HRG contains an additional half-cystine at posi- 
tion 279, which is absent in the human counterpart. 
Consequently, the disulphide bridge arrangement deter- 
mined in this study does not allow us to predict the 
complete disulphide bridge pattern of human HRG. 
However, the amino acid sequence in the N- and C- 
termini of bovine HRG shows an extensive similarity to 
the human counterpart, including the positions of the 
half-cystines. It seems very likely that the half-cystines 
in these areas are involved in identical disulphide 
bridges in the two proteins. Therefore we suggest that 
disulphide bridges I. II, III, IV, and V established in this 
study are present in human HRG, too. 
The N-terminal region of human HRG (residues l- 
225) contains two cystatin-like domains [22]. These do- 
mains show homology towards known members of the 
cystatin superfamily, including the positions of the half- 
cystines and the amino acid residues surrounding these. 
Due to this homology. HRG was proposed to belong 
to the cystatin superfamily, constituting a new fourth 
family, although no inhibitor function has been demon- 
strated for HRG [22]. The determination of the dis- 
ulphide bridge arrangement in bovine HRG confirms 
the placement of HRG in the cystatin superfamily. Fur- 
thermore, the results clarify why the first half-cystine in 
cystatin-like domain I in HRG (residues 1-112) is not 
part of a cystatin-domain. since it is involved in dis- 
ulphide bridge formation with the last half-cystine resi- 
due in the molecule. Likewise, the first half-cystine res- 
idue in the second cystatin-like domain (residues 113- 
225) is lacking, which makes this cystatin-like domain 
different from those of the other members of the super- 
family. Consequently, the second half-cystine in this 
domain must be engaged in disulphide bridge formation 
with a different half-cystine, shown in this study to be 
cys-399. 
Like in human HRG. a C-terminal lysine was found 
in bovine HRG, which may account for the ability of 
HRG to bind plasminogen. In addition, a second lysine 
is located eight amino acids towards the N-terminal of 
bovine HRG, a motif which has been suggested to en- 
hance the binding affinity of proteins for plasminogen 
[27]. Heterogeneity with respect to carbohydrate was 
identified at position 74 and polymorphism with respect 
to amino acid residues was found at positions 102,420, 
and 433 suggesting that there are more than one allele 
of the bovine HRG gene giving rise to different allelic 
forms of the gene-product or alternatively, more than 
one gene for HRG. An acid hydrolysis caused by formic 
acid during CNBr-treatment occurs in the C-terminal 
part of the protein (between Xaa-414 and Pro-415). This 
observation is in accordance with an Asp-Pro hydroly- 
sis (between Asp-400 and Pro-401) in human HRG 
The disulphide bonds in the members of the cystatin 
superfamily have been described in general terms. Four 
different kinds of disulphide loops, A, B, C, and D have 
been characterized [29,30]. These are schematically out- 
lined in Fig. 2. Type A and B represent the first and 
second loop of a cystatin domain, respectively, and both 
are found in the cystatin family (family 2), the kininogen 
family (family 3) and in human a,-HS glycoprotein. 
The latter does not exhibit any inhibitor function and 
has been placed in family 4 together with HRG [30]. 
Type C and D loops are found in the kininogens and 
in human a,-HS glycoprotein, both of which become 
two-chained molecules by proteolysis and excision of a 
peptide. Type C and D loops are not part of the cystatin 
domains. Type C loops span 4 residues and are placed 
in between cystatin domains whereas type D loops span 
the entire molecule by connejcting the extreme N- and 
C-termini of the proteins. 
The present study reveals that bovine HRG likewise 
contains one type D loop in addition to one type A and 
two type B loops. Furthermore, the disulphide bridge 
arrangements of human and bovine HRG are not iden- 
tical, in contrast to the disulphide bridge patterns found 
in kininogens of different species (e.g. man and cow) 
[29,31]. Whether the proteolytic split between Arg-297 
and Ala-298 represents a physiological proteolysis and 
excision of a fragment, by analogy with kininogens and 
a,-HS-glycoprotein remains to be shown, but it would 
explain the presence of a type D loop in the molecule 
even though two other disulphide bridges are connect- 
ing the two parts of the protein. 
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